Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States.

Rothschild AJ, Mahableshwarkar AR, Jacobsen P, Yan M, Sheehan DV.

Eur Neuropsychopharmacol. 2012 Dec;22(12):858-66. doi: 10.1016/j.euroneuro.2012.07.011.

PMID:
22901736
2.

Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial.

Bidzan L, Mahableshwarkar AR, Jacobsen P, Yan M, Sheehan DV.

Eur Neuropsychopharmacol. 2012 Dec;22(12):847-57. doi: 10.1016/j.euroneuro.2012.07.012.

PMID:
22898365
3.

A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder.

Mahableshwarkar AR, Jacobsen PL, Serenko M, Chen Y.

Hum Psychopharmacol. 2014 Jan;29(1):64-72. doi: 10.1002/hup.2371.

PMID:
24424707
4.

A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.

Mahableshwarkar AR, Jacobsen PL, Chen Y.

Curr Med Res Opin. 2013 Mar;29(3):217-26. doi: 10.1185/03007995.2012.761600.

PMID:
23252878
5.
7.

A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.

Jain R, Mahableshwarkar AR, Jacobsen PL, Chen Y, Thase ME.

Int J Neuropsychopharmacol. 2013 Mar;16(2):313-21. doi: 10.1017/S1461145712000727.

PMID:
22963932
8.

A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder.

Jacobsen PL, Mahableshwarkar AR, Serenko M, Chan S, Trivedi MH.

J Clin Psychiatry. 2015 May;76(5):575-82. doi: 10.4088/JCP.14m09335.

9.

Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder.

Baldwin DS, Loft H, Florea I.

Int Clin Psychopharmacol. 2012 Jul;27(4):197-207. doi: 10.1097/YIC.0b013e3283530ad7.

PMID:
22475889
10.

A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD).

Baldwin DS, Loft H, Dragheim M.

Eur Neuropsychopharmacol. 2012 Jul;22(7):482-91. doi: 10.1016/j.euroneuro.2011.11.008.

PMID:
22209361
11.

A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder.

Henigsberg N, Mahableshwarkar AR, Jacobsen P, Chen Y, Thase ME.

J Clin Psychiatry. 2012 Jul;73(7):953-9. doi: 10.4088/JCP.11m07470.

PMID:
22901346
12.

Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.

Naukkarinen H, Raassina R, Penttinen J, Ahokas A, Jokinen R, Koponen H, Lepola U, Kanerva H, Lehtonen L, Pohjalainen T, Partanen A, Mäki-Ikola O, Rouru J; Deramciclane Dose-Finding Study Group..

Eur Neuropsychopharmacol. 2005 Dec;15(6):617-23.

PMID:
15949921
13.

A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD.

Mahableshwarkar AR, Jacobsen PL, Chen Y, Serenko M, Trivedi MH.

Psychopharmacology (Berl). 2015 Jun;232(12):2061-70. doi: 10.1007/s00213-014-3839-0.

14.

Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: a systematic review and meta-analysis.

Pae CU, Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Serretti A.

J Psychiatr Res. 2015 May;64:88-98. doi: 10.1016/j.jpsychires.2015.02.017. Review.

PMID:
25851751
15.

A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder.

Mahableshwarkar AR, Jacobsen PL, Serenko M, Chen Y, Trivedi MH.

J Clin Psychiatry. 2015 May;76(5):583-91. doi: 10.4088/JCP.14m09337.

16.

Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study.

Wang G, Gislum M, Filippov G, Montgomery S.

Curr Med Res Opin. 2015 Apr;31(4):785-94. doi: 10.1185/03007995.2015.1014028.

PMID:
25650503
17.

An evaluation of the anxiolytic SC 48,274 in generalized anxiety disorder (GAD)

Cutler NR, Sramek JJ, Macpherson AE, Doss MG, Benes CO, Howard SF.

Prog Neuropsychopharmacol Biol Psychiatry. 1994 Jul;18(4):685-94.

PMID:
7938559
18.

A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder.

Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RS.

Neuropsychopharmacology. 2015 Jul;40(8):2025-37. doi: 10.1038/npp.2015.52.

19.

Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial.

Rickels K, Mathew S, Banov MD, Zimbroff DL, Oshana S, Parsons EC Jr, Donahue SR, Kauffman M, Iyer GR, Reinhard JF Jr.

J Clin Psychopharmacol. 2008 Apr;28(2):235-9. doi: 10.1097/JCP.0b013e31816774de.

PMID:
18344738
20.

Duloxetine: a review of its use in the treatment of generalized anxiety disorder.

Carter NJ, McCormack PL.

CNS Drugs. 2009;23(6):523-41. doi: 10.2165/00023210-200923060-00006. Review.

PMID:
19480470
Items per page

Supplemental Content

Support Center